Senior Biotech/Pharma Executive. Business Development. Product Development. R&D. Production. Pharma/Biotech Consultancy
Senior executive with Board Level and international/cross-cultural experience in the pharmaceutical and biotechnology industry with in-depth knowledge of Research, Product Development, Business Development and cGMP manufacture in Oncology, CNS, anti-viral/anti-infectives and Cardiovascular fields as well as corporate restructuring and collaborating with Venture Capital investors. Wide network of high level contacts in the industry around the world. Multi lingual and multi cultural. Member of GLG Healthcare Councils and Reuters Insight global consultancy groups. EU Expert Evaluator. Expert at BioExpert Network. Specialties: Product Development. Business Development functions - licenses, supply and development negotiation/agreements. Project Management. Business Unit creation/management. Team Management. Corporate Restructuring. Senior Management.
Ask me about
Feb 2018 - Present
IESE Business School
Facilitator/Mentor - Executive Action Learning Team, Learning Innovation Unit
Jul 2014 - Present
Chief Business Officer - ADAN Medical Innovation. Medical Device company which has developed a digital health 'smart case' for autoinjectors such as Epipen; helping with licensing, financing, product roll-out agreements. Corporate Advisor - DisruPep. Development of a disruptive novel treatment for PTSD. Interim Management. Registered EU Expert Evaluator EASME; H2020 Programme. Expert at BioExpert Network. Advising US, EU and Asian Private Equity funds on acquisition/investment targets in the pharma sector. Assisting biotechnology and MedTech/Device companies with Fund Raising, Product Development and Business Development activities. Business Diversification advice, manufacture for clinical supply, preclinical development, out-licensing support.
Jan 2009 - May 2014
Specialty pharmaceutical company working on the design and development of novel oncology drugs in the epigenetics area. Winners of the 2010 La Caixa Emprendedor XXI prize for best managed, most promising Spanish company. - Raised important funds in difficult economic climate from Venture Capital investors, EU and National/Regional Government funding bodies. - Negotiated and closed Licensing deal with a Japanese pharma company. - Closed and managed co-development agreements with European institutions. - Advanced two products through development managing costs effectively and educating team in pharmaceutical industry development procedures.
Sep 2005 - Dec 2008
Independent Consultant advising Pharma/Biotech companies on Product Development and Business Development. - Restructured small Biotech company at request of Venture Capital investor, organising team into operating units streamlining functions and increasing efficiency. - Advised IkerChem on Business and Product Development plan which led to appointment as company CEO. - Manufacturing and Process Development projects; Product Development; Business Development
May 2002 - Jul 2005
Director Business Development
Member of Board of Directors. Director of Contract Manufacturing business unit. - Created and managed new business unit achieving development and supply agreements in USA, EU, Japan and Australia. - Managed all commercial and technical operations (R+D/Production) of unit.
Sep 1995 - Apr 2002
Director Marketing / New Product Development
Member of Board of Directors. - Managed selection and development of new products resulting in the launch of various new products for the company product portfolio. - Built 3rd party manufacturing business unit growing business from <$1 million/year to >$20 million/year across four manufacturing sites in EU and Mexico, achieving preferred supplier status with multinational companies and creating new business within the biotechnology sector. - Managed Regulatory Affairs group.
Jan 1992 - Sep 1995
CRO for Pharma/Biotech/MedicalDevice/Chemical industry. - Led Business Development in Asia, mainly Japan,growing business from 60 clients to >300 clients. - Opened Korean market for company. Also various important contacts within EU and USA.
Jan 1989 - Dec 1991
Daiichi Pharmaceuticals Group
Project/Staff Management in pharmaceutical R&D - synthesis; safety evaluation; pharmacokinetics. Also assisted in business development activities.
1982 - 1985
Leading European Biotechnology company. Organic Synthesis related to biotechnology research. Synthesis of oligonucleotides.